Solaymani-Dodaran Masoud, Logan Richard F A, West Joe, Card Tim
University of Nottingham, Division of Epidemiology and Public Health, Medical School, Queen's Medical Centre, Nottingham, UK.
Am J Gastroenterol. 2005 Dec;100(12):2616-21. doi: 10.1111/j.1572-0241.2005.00340.x.
Patients with Barrett's esophagus have a much increased risk of esophageal adenocarcinoma but recent evidence suggests no increase in overall mortality. We have reexamined this surprising finding in a large, prospectively population-based cohort study.
Cohorts of patients having Barrett's esophagus (n=1,677), esophagitis (n=6,392), simple reflux (n=6,328), and a standard reference cohort representing the general population in the United Kingdom (n=13,416) were selected from General Practice Research Database. The last three cohorts were matched to the Barrett's cohort by general practice, age, and sex. Mortality rates and hazard ratios with their 95% confidence intervals were calculated for deaths due to all causes and deaths due to all causes except esophageal cancer occurring beyond the first year of the follow-up.
A total of 1,725 deaths were analyzed including 49 deaths in subjects having esophageal cancer. Of 111 deaths in the Barrett's cohort, 13 (12%) were in subjects with esophageal cancer. Compared with the reference cohort, hazard ratios for all causes of death were 1.37 (1.12-1.66) for the Barrett's, 1.16 (1.02-1.32) for the esophagitis, and 1.16 (1.01-1.33) for the reflux cohorts. The corresponding figures for deaths due to all causes except esophageal cancer were 1.23 (1.00-1.51), 1.13 (0.99-1.30), and 1.15 (1.00-1.31). Of the excess mortality rates in the Barrett's, esophagitis, and reflux cohorts, at the most 45%, 20%, and 13%, respectively, could be attributed to esophageal cancer.
People with Barrett's esophagus and gastroesophageal reflux disease have higher mortality rates than the general population, and an increase in esophageal cancer risk accounts for less than half the excess mortality in Barrett's.
巴雷特食管患者患食管腺癌的风险大幅增加,但最近的证据表明总体死亡率并未上升。我们在一项大型前瞻性人群队列研究中重新审视了这一惊人发现。
从全科医学研究数据库中选取了患有巴雷特食管(n = 1677)、食管炎(n = 6392)、单纯反流(n = 6328)的患者队列,以及代表英国普通人群的标准参考队列(n = 13416)。后三个队列通过全科医疗、年龄和性别与巴雷特队列进行匹配。计算了随访第一年之后所有原因导致的死亡以及除食管癌外所有原因导致的死亡的死亡率和风险比及其95%置信区间。
共分析了1725例死亡病例,其中49例死于食管癌。在巴雷特队列的111例死亡中,13例(12%)死于食管癌。与参考队列相比,巴雷特队列所有原因导致死亡的风险比为1.37(1.12 - 1.66),食管炎队列是1.16(1.02 - 1.32),反流队列是1.16(1.01 - 1.33)。除食管癌外所有原因导致死亡的相应数字分别为1.23(1.00 - 1.51)、1.13(0.99 - 1.30)和1.15(1.00 - 1.31)。在巴雷特、食管炎和反流队列的额外死亡率中,最多分别有45%、20%和13%可归因于食管癌。
患有巴雷特食管和胃食管反流病的人群死亡率高于普通人群,食管癌风险增加占巴雷特人群额外死亡率的不到一半。